About Us | Contact Us |        

Updating and Advancing the Management of DMD Therapy in Multiple Sclerosis

Neurology
Curriculum:
Updating and Advancing the Management of DMD Therapy in MS
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
November 06, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Neurologists and other health care providers actively involved in the care of patients with multiple sclerosis (MS)

Relevant Terms:

BG-12, Biomarkers, Clinically Isolated Syndrome, Dimethyl Fumurate, Disease-modifying Drugs, Fingolimod, Glatiramer Acetate, MRI, MS Diagnosis, Multiple Sclerosis, Natalizumab, Pegylated Interferon, Radiologically Isolated Syndrome, Teriflunomide

Aaron Boster, MD

Aaron Boster, MD
Assistant Professor of Neurology
Division Head, Neuro-Immunology
Director, Ohio State University MS Center
Columbus, OH

Aaron Boster, MD is a native of Columbus, OH. He graduated with majors in neuroscience and psychology from Oberlin College in Ohio then matriculated to the University of Cincinnati College of Medicine. He completed his internal medicine internship and neurology residency at the University of Michigan in Ann Arbor, MI.
                      
After completing fellowship training in clinical neuroimmunology and multiple sclerosis at Wayne State University, he joined the faculty in the Neurology Department at Ohio State University (OSU) in 2008. Currently, Dr. Boster is an Assistant Professor of Neurology and Director the OSU Multiple Sclerosis Center and MS Clinical Trials Program. He also directs the OSU Neurology Spasticity Program, where he specializes in intrathecal baclofen therapy (ITB) therapy for the multiple sclerosis patient. He lives in Columbus, OH with his wife and 2 children.

Suhayl Dhib-Jalbut, MD

Suhayl Dhib-Jalbut, MD
Professor and Chairman
Department of Neurology
Rutgers-Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ

Suhayl Dhib-Jalbut, MD is Professor and Chairman of the Department of Neurology at Rutgers-Robert Wood Johnson Medical School, and Chief of Neurology at the Robert Wood Johnson University Hospital. He is also Director of the RWJ Center for Multiple Sclerosis (MS).

Dr. Dhib-Jalbut graduated Alpha-Omega-Alpha from the American University of Beirut in Lebanon and completed his neurology training at the University of Cincinnati. He then joined the National Institutes of Health (NIH) in Bethesda, MD, where he specialized in MS and neuroimmunology. In 1990, Dr. Dhib-Jalbut joined the faculty of the University of Maryland in Baltimore, where he established a research program in MS before his recruitment to Robert Wood Johnson Medical School in 2003.

Dr. Dhib-Jalbut's research – which has been funded by the NIH, the National MS Society, and industry sources – includes studies on how MS therapies work, biomarkers of treatment response in MS, and neuroprotective gene therapy. Dr. Dhib-Jalbut published more than 100 manuscripts in the scientific literature, and served as Associate Editor for the Journal of Neuroimmunology. He currently serves on the Editorial Boards of Journal of Interferon & Cytokine Research (JICR) and MS International. He served on several national and international scientific committees, including Chairmanship of the Scientific Committee for the World Congress on MS in 2008. Dr. Dhib-Jalbut has been on the Best Doctors in America list since 2009 and has received several awards and recognitions. Most recently, he was awarded the Norman H. Edelman Clinical Science Mentoring Award at Rutgers, the Medical Excellence Award by the National MS Society NJ Metro Chapter, and the Edward Ill Award for Excellence in Clinical Research in the State of New Jersey. Dr. Dhib-Jalbut currently serves as President of the Americas Committee for Treatment and Research in MS (ACTRIMS).

Aaron E. Miller, MD

Aaron E. Miller, MD
Professor of Neurology
Icahn School of Medicine at Mount Sinai
Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY

Aaron E. Miller, MD is Professor of Neurology at the Icahn School of Medicine at Mount Sinai and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis. He is widely recognized for his preeminence as an MS clinician and thought-leader.
 
Dr. Miller graduated from Brandeis University in 1964 and received his medical doctorate from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at Einstein. During this time, he was the recipient of a fellowship from the National MS Society. In March 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai School of Medicine. For 23 years prior, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY, where he continues to serve as Co-director of the MS Care Center. 

Dr. Miller has been the Chief Medical Officer of the National MS Society (NMSS) since October 2001, and served as Chairman of the National Medical Advisory Board of the NMSS from 2001-2009. He has been a member of the NMSS Board of Directors since 2003. He was the first Chairman of the Multiple Sclerosis Section of the American Academy of Neurology, and has participated in numerous clinical trials of new treatments for MS. 
 
Dr. Miller is active within the American Academy of Neurology (AAN), and serves as a member of the Board of Directors. From 2003-2012, he was Editor of Continuum, AAN's bimonthly continuing education publication, and continues to serve as Editor of Continuum Audio. Dr. Miller has served as Principal Investigator for many clinical trials in MS and has been a member of many data and safety monitoring boards. He is the co-author of 2 books on MS and related disorders and has published many peer-reviewed articles and book chapters.
1. Employ newer MRI measures to improve diagnosis and DMD therapy initiation earlier in the course of MS
2. Analyze the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies to develop individualized MS therapies that optimize adherence and improve patient outcomes
3. Incorporate evidence from recent diagnostic and prognostic biomarker studies to improve monitoring of disease activity and response to DMD therapy in MS

Program Overview/Description of Need: The diagnosis and management of multiple sclerosis (MS) is evolving with the ongoing emergence of disease-modifying drugs (DMDs), newer diagnostic criteria, and MRI measures and biomarkers capable of improving disease surveillance. Combined with a continued push for earlier diagnosis and initiation of DMD therapy, MS diagnosis and management is becoming increasingly complex. Clinicians face more treatment choices, making the formulation of optimal DMD therapies increasingly difficult. In addition, patient concerns with DMD side effects, treatment preferences, drug costs, and other issues continue to negatively impact patient acceptance of and adherence to DMD treatments.

Updating and Advancing the Management of DMD Therapy in Multiple Sclerosis will review the latest research and clinical management information on DMD therapies, diagnostic MRI measures, and biomarkers, in order to provide neurologists and other MS specialists with the knowledge and skills needed to improve the management of patients with MS.

Target Audience: This activity is intended for neurologists and other health care providers actively involved in the care of patients with multiple sclerosis (MS).

DISCLOSURE POLICY STATEMENT

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
 
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
 
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
 
Faculty Disclosures
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
 
Aaron Boster, MD:  Advisory Board: Biogen, Genzyme, Medtronic, Novartis, Teva

Suhayl Dhib-Jalbut, MD:  Consultant: AbbVie, Bayer, Novartis, Teva, Serono; Grant Support: Novartis, Teva
 
Aaron E. Miller, MD: Consultant: Acorda Therapeutics, Accordant Health Services (Caremark), Biogen Idec, EMD Serono, Genzyme/Sanofi-Aventis, GlaxoSmithKline, Novartis, Nuron Biotech; Research Support: Acorda Therapeutics, Biogen Idec, Genentech, Genzyme/Sanofi-Aventis, Novartis, Roche, Questcor
                                              
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Matthew Horn, MD; Blair St. Amand; Jay Katz, CCMEP; Dana S. Simpler, MD: Nothing to disclose
 
DISCLOSURE ATTESTATION
 
DISCLAIMER
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
 
PHYSICIAN CREDIT DESIGNATION
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
 
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This continuing medical education activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.

COMMERCIAL SUPPORT
This program is supported by educational grants from Teva Neuroscience, Novartis Pharmaceuticals Corporation, and Bayer Healthcare.
 
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
 

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 80% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above